A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, EFFICACY AND SAFETY STUDY OF OLUMACOSTAT GLASARETIL GEL IN SUBJECTS WITH ACNE VULGARIS

Intervention/treatment:
OLUMACOSTAT
Medical condition:
ACNE
Protocol code:
DRM01B-ACN03
Control number:
201091
Status:
Closed
Approved:
January 11, 2017
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03028363
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
9 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Chief Medical Officer
Organization
Eli Lilly and Company.
Phone:
800-545-5979
Sponsor
DERMIRA INCORPORATED

Locations

Alberta

Institute for Skin Advancement
Calgary, Alberta, T3A 2N1

Ontario

Lynderm Research Inc.
Markham, Ontario, L3P 1X2
North Bay Dermatology Centre
North Bay, Ontario, P1B 3Z7
Research Toronto
Toronto, Ontario, M4W 2N2
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, L4M 7G1
Windsor Research Inc.
Windsor, Ontario, N8W 5L7

Results

See the results from the trial NCT03028363. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?